S. Verma

Epidemiology · Circulation · 2002–2021

A researcher in the Science corpus: 18 papers; trusts 5 researchers and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Epidemiology — 69 citations into it
• Cardiology and Cardiovascular Medicine — 65 citations into it
• Surgery — 41 citations into it
• Immunology — 34 citations into it
• Molecular Biology — 31 citations into it
• Hematology — 12 citations into it
• Cancer Research — 11 citations into it
• Genetics — 6 citations into it

Whom S. Verma trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. P. Ridker
2. Peter Libby
3. J. Willerson
4. S. Coughlin
5. E. Ferrannini
6. N. Rifai
7. W. Aird
8. T. Anderson

Who trusts S. Verma overall

1. K. Sugamura

Papers from S. Verma's perspective

Ordered by how strongly the researchers S. Verma trusts endorse each paper. Same corpus, a different order for every researcher.

1. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. (Journal of the American Medical Association (JAMA))
2. Myocardial fatty acid metabolism in health and disease. (Physiological Reviews)
3. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. (Journal of the American Medical Association (JAMA))
4. Evolving functions of endothelial cells in inflammation (Nature reviews. Immunology)
5. Endothelial cell diversity revealed by global expression profiling (Proceedings of the National Academy of Sciences of the United States of America)
6. Molecular motors
7. Obesity in the new millennium (Nature)
8. Protease‐activated receptors in hemostasis, thrombosis and vascular biology (Journal of Thrombosis and Haemostasis)
9. The war against heart failure: the Lancet lecture. (The Lancet)
10. Endothelial dysfunction. (Circulation)

Their papers

• A Self-Fulfilling Prophecy: C-Reactive Protein Attenuates Nitric Oxide Production and Inhibits Angiogenesis (2002) — 1,156 citations
• Low-Dose Methotrexate for the Prevention of Atherosclerotic Events (2018) — 1,101 citations
• New Markers of Inflammation and Endothelial Cell Activation: Part I (2003) — 793 citations
• Empagliflozin in Heart Failure with a Preserved Ejection Fraction. (2021) — 3,081 citations
• Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure (2020) — 3,699 citations
• Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. (2020) — 1,345 citations
• Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors (2020) — 728 citations
• Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. (2019) — 5,091 citations
• SGLT2 inhibitors and mechanisms of cardiovascular benefit: a state-of-the-art review (2018) — 847 citations
• Restrictive or Liberal Red‐Cell Transfusion for Cardiac Surgery (2017) — 629 citations
• Endothelial cell control of thrombosis (2015) — 620 citations
• Altered Expression of Disintegrin Metalloproteinases and Their Inhibitor in Human Dilated Cardiomyopathy (2006) — 106 citations
• Adipokines: molecular links between obesity and atheroslcerosis. (2005) — 1,001 citations
• Resistin Promotes Endothelial Cell Activation: Further Evidence of Adipokine-Endothelial Interaction (2003) — 716 citations
• Endothelial function testing as a biomarker of vascular disease. (2003) — 607 citations
• Clinical and Pathophysiological Implications of a Bicuspid Aortic Valve (2002) — 770 citations
• Endothelin Antagonism and Interleukin-6 Inhibition Attenuate the Proatherogenic Effects of C-Reactive Protein (2002) — 677 citations
• Fundamentals of endothelial function for the clinical cardiologist. (2002) — 667 citations